4.3 Review

Management of morning hypertension: a consensus statement of an Asian expert panel

期刊

JOURNAL OF CLINICAL HYPERTENSION
卷 20, 期 1, 页码 39-44

出版社

WILEY
DOI: 10.1111/jch.13140

关键词

ambulatory blood pressure; antihypertensive treatment; home blood pressure; morning blood pressure; morning hypertension

资金

  1. Bayer
  2. Boehringer-Ingelheim
  3. Daiichi-Sankyo
  4. MSD
  5. Novartis
  6. Omron
  7. Pfizer
  8. Sanofi
  9. Servier
  10. Fukuda Denshi
  11. Omron Healthcare
  12. Bayer Yakuhin
  13. MSD K.K.
  14. Mochida Pharmaceutical
  15. Novartis Pharma K.K.
  16. Sumitomo Dainippon Pharma
  17. Boehringer Ingelheim Japan
  18. Daiichi Sankyo
  19. Takeda Pharmaceutical
  20. Astellas Pharma
  21. Teijin Pharma
  22. Bristol-Myers K.K
  23. Shionogi

向作者/读者索取更多资源

Morning blood pressure (BP) surge is an important aspect of hypertension research. Morning BP monitoring could be a clinically relevant concept in the therapeutic management of hypertension and in the prevention of cardiovascular complications by defining and treating morning hypertension. Because antihypertensive medication is often taken in the morning, uncontrolled morning BP during the trough effect hours could be a hallmark of inadequate choice of antihypertensive regimen, such as the use of short- or intermediate-acting drugs, underdosing of drugs, or no use or underuse of combination therapy. To improve the management of hypertension in general and morning hypertension in particular, long-acting antihypertensive drugs should be used in appropriate, often full dosages and in proper combinations. The clinical usefulness of antihypertensive drugs with specific mechanisms for morning BP or split or timed dosing of long-acting drugs in controlling morning BP remains under investigation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据